



## Process Characterization

## Product Characterization




- Completed > 40 Characterization Projects
- Supported > 15 Regulatory Submissions
- Worked with > 10 Biosimilar Developers Worldwide

*Diversity of Process Linked Characterization Project Completed*



*Diversity of Product Linked Characterization Project Completed*



### Some of the Product that we have Characterized

- Trastuzumab
- Dengue mAb
- Rituximab
- Bevacizumab
- EGFR
- Erythropoietin
- FHA
- CRM197
- Diphtheria Toxin and Toxoid
- Tetanus Toxin and Toxoid
- Pertactin and Pertussis Toxins
- Hepatitis-B
- HPV6 / HPV11 / HPV16 / HPV18
- Bacillus Calmette–Guérin (BCG)
- Interferon–beta (INF- $\beta$ ) / PEGylated INF- $\beta$
- Low Molecular Weight Heparin (LMWH)